NCT06740526 is a Phase 2 clinical trial of Sibeprenlimab in IgA Nephropathy, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc..

Who is sponsoring NCT06740526?

NCT06740526 is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc..

What drugs are being tested in NCT06740526?

Interventions in NCT06740526: Sibeprenlimab.

What condition does NCT06740526 study?

NCT06740526 studies IgA Nephropathy.

Is NCT06740526 still recruiting?

NCT06740526 is currently recruiting now. Last updated 6 April 2025.

Last reviewed 2025-04-06 · How we verify

NCT06740526

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

Recruiting now Phase 2 Last updated 6 April 2025

What this trial tests

Phase 2 trial testing Sibeprenlimab in IgA Nephropathy in 25 participants. Currently enrolling.

Timeline

19 November 2024

Primary endpoint
17 April 2029

17 April 2029

Quick facts

Lead sponsor	Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	19 November 2024
Primary completion	17 April 2029
Estimated completion	17 April 2029
Sites	5 locations across Canada, United States

Drugs / interventions tested

Sibeprenlimab — full drug profile →

Conditions studied

IgA Nephropathy — all drugs for IgA Nephropathy →

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. — full company profile →

Who can join

16 and older, any sex, with IgA Nephropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 2b open-label trial to characterize histopathological biomarkers of disease in immunoglobulin A nephropathy (IgAN) and demonstrate potential changes in response to sibeprenlimab.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

IgA Nephropathy: An Overview of the Clinical Trials.
Gholizadeh Ghozloujeh Z, Selvaskandan H, Wiegley N, Lerma E, et al · · 2025 · cited 3× · PMID 41050133 · DOI 10.1016/j.xkme.2025.101078
Recent Advancements in the Therapeutic Landscape of IgA Nephropathy and the Impact of Dual Blockers: Telitacicept.
Munisamy Selvam KK, Feng C, Dong S. · · 2026 · PMID 42206210 · DOI 10.1016/j.xkme.2026.101354

Verify or expand the search:

Other trials of Sibeprenlimab

Trials testing the same drug.

NCT06928142 — A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's · Phase 2 · active not recruiting
NCT07105124 — Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject · Phase 1 · completed

Other recruiting trials for IgA Nephropathy

Currently open trials in the same condition.

NCT07030894 — Nefecon and Ambrisentan in IgA Nephropathy · Phase 4 · recruiting
NCT06767592 — A Study of Probiotics in IgA Nephropathy · NA · recruiting
NCT05852938 — A Study of Zigakibart in Adults With IgA Nephropathy · Phase 3 · active not recruiting
NCT05942625 — A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects · Phase 1 · recruiting
NCT05775042 — Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy · Phase 2 · recruiting

Other Otsuka Pharmaceutical Development & Commercialization, Inc. trials

Trials by the same sponsor.

NCT07525960 — A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for · Phase 1 · not yet recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07455084 — A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults · Phase 1 · not yet recruiting
NCT07314333 — A Trial to Assess How Centanafadine Interacts With Stimulants in the Body · Phase 1 · recruiting
NCT07329621 — A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06740526 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Otsuka Pharmaceutical Development & Commercialization, Inc.
Last refreshed: 6 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06740526.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing